Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Atlantic Union Bankshares Corp

Atlantic Union Bankshares Corp cut its holdings in Bristol-Myers Squibb (NYSE:BMY) by 6.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 30,094 shares of the biopharmaceutical company’s stock after selling 1,916 shares during the period. Atlantic Union Bankshares Corp’s holdings in Bristol-Myers Squibb were worth $1,702,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Dorsey & Whitney Trust CO LLC boosted its holdings in shares of Bristol-Myers Squibb by 6.8% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 35,288 shares of the biopharmaceutical company’s stock valued at $1,996,000 after buying an additional 2,247 shares during the period. Rialto Wealth Management LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $84,000. Larson Financial Group LLC lifted its position in Bristol-Myers Squibb by 10.6% in the 4th quarter. Larson Financial Group LLC now owns 17,100 shares of the biopharmaceutical company’s stock valued at $967,000 after purchasing an additional 1,639 shares during the last quarter. HM Payson & Co. lifted its position in Bristol-Myers Squibb by 8.4% in the 4th quarter. HM Payson & Co. now owns 97,869 shares of the biopharmaceutical company’s stock valued at $5,535,000 after purchasing an additional 7,583 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $1,012,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. BMO Capital Markets lifted their price objective on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research report on Tuesday, November 12th. Truist Financial lifted their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Wolfe Research assumed coverage on shares of Bristol-Myers Squibb in a research report on Friday, November 15th. They issued a “peer perform” rating on the stock. Leerink Partners upgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Finally, Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Stock Up 1.6 %

NYSE BMY opened at $61.16 on Friday. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The company’s 50 day simple moving average is $57.39 and its 200 day simple moving average is $55.13. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.11. The company has a market capitalization of $124.11 billion, a P/E ratio of -13.84, a PEG ratio of 2.07 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Equities research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 4.05%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -56.11%.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 1,823 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now directly owns 63,932 shares in the company, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is currently owned by insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.